EXTON, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, Chairman and Chief Executive Officer, will present at the 2015 Wedbush PacGrow Healthcare Conference at 8:00 am EDT on Tuesday, August 11, 2015 in New York City.
A live webcast of Fibrocell's presentation will be available on the Company's website at fibrocell.com/investors/events-and-presentations and archived for 30 days.
About Fibrocell Science, Inc.
Fibrocell is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin diseases using gene-modified autologous fibroblasts. Fibrocell has submitted an IND application to the FDA for FCX-007, its lead orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in preclinical development of FCX-013, its second gene-therapy product candidate, for the treatment of linear scleroderma. For more information, visit fibrocell.com.
CONTACT: Investor Relations & Media Contact: Karen Casey Fibrocell Science, Inc. +1 (484) 713-6133 email@example.comSource:Fibrocell Science, Inc.